Figure 3

Gene and protein expressions of inflammatory and anti-inflammatory biomarkers on day 14 after AMI in infarcted area. A & B) Notably higher mRNA expressions of plasminogen activator inhibitor (PAI)-1 and matrix metalloproteinase (MMP)-9 in AMI than in normal and AMI + tacrolimus, and significantly higher in AMI + tacrolimus than in normal. * vs. other groups, p < 0.001. C) Significantly higher mRNA expression of interleukin (IL)-10 in AMI + tacrolimus than in AMI and normal, and remarkably higher in AMI than in normal. * vs. other groups, p < 0.0001. D) Remarkably higher mRNA expression of endothelial nitric oxide synthase (eNOS) in AMI + tacrolimus than in normal and AMI, and markedly increased in normal than in AMI. * vs. other groups, p < 0.001. E) Substantially higher protein expression of eNOS in normal than in AMI + tacrolimus and AMI, and notably higher in AMI + tacrolimus than in AMI. * vs. other groups, p < 0.01. F) Significantly higher protein expression of nuclear factor (NF)-κB (p65) in AMI than in normal and AMI + tacrolimus. * vs. other groups, p < 0.01. G) Significantly higher protein expression of tumor necrotic factor (TNF)-α in AMI than in normal and AMI + tacrolimus, and notably higher in AMI + tacrolimus than in normal. * vs. other groups, p < 0.001. All statistical analyses using one-way ANOVA, followed by Tukey’s multiple comparison procedure. Symbols (*, †, ‡) indicate significance (at 0.05 level).